AU2015292048B2 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
AU2015292048B2
AU2015292048B2 AU2015292048A AU2015292048A AU2015292048B2 AU 2015292048 B2 AU2015292048 B2 AU 2015292048B2 AU 2015292048 A AU2015292048 A AU 2015292048A AU 2015292048 A AU2015292048 A AU 2015292048A AU 2015292048 B2 AU2015292048 B2 AU 2015292048B2
Authority
AU
Australia
Prior art keywords
group
mmol
imidazo
oxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015292048A
Other languages
English (en)
Other versions
AU2015292048A1 (en
Inventor
Eric Steven Manas
Christopher Ernst NEIPP
Vipulkumar Kantibhai Patel
Joseph E. Pero
Raphael Anthony RIVERO
Matthew Robert SENDER
Zehong Wan
Jian Wang
Xiaomin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2015292048A1 publication Critical patent/AU2015292048A1/en
Application granted granted Critical
Publication of AU2015292048B2 publication Critical patent/AU2015292048B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015292048A 2014-07-22 2015-07-21 Compounds Ceased AU2015292048B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014000695 2014-07-22
CNPCT/CN2014/000695 2014-07-22
PCT/CN2015/084606 WO2016011930A1 (en) 2014-07-22 2015-07-21 Compounds

Publications (2)

Publication Number Publication Date
AU2015292048A1 AU2015292048A1 (en) 2016-12-15
AU2015292048B2 true AU2015292048B2 (en) 2017-06-29

Family

ID=55162512

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015292049A Ceased AU2015292049B2 (en) 2014-07-22 2015-07-21 Compounds
AU2015292048A Ceased AU2015292048B2 (en) 2014-07-22 2015-07-21 Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2015292049A Ceased AU2015292049B2 (en) 2014-07-22 2015-07-21 Compounds

Country Status (14)

Country Link
US (5) US9783546B2 (US07094801-20060822-C00173.png)
EP (2) EP3172211B1 (US07094801-20060822-C00173.png)
JP (2) JP6625603B2 (US07094801-20060822-C00173.png)
KR (2) KR20170029516A (US07094801-20060822-C00173.png)
CN (2) CN106536525B (US07094801-20060822-C00173.png)
AR (1) AR101261A1 (US07094801-20060822-C00173.png)
AU (2) AU2015292049B2 (US07094801-20060822-C00173.png)
BR (1) BR112016030939B1 (US07094801-20060822-C00173.png)
CA (2) CA2955910C (US07094801-20060822-C00173.png)
ES (2) ES2747636T3 (US07094801-20060822-C00173.png)
RU (2) RU2017105476A (US07094801-20060822-C00173.png)
TW (1) TW201617348A (US07094801-20060822-C00173.png)
UY (1) UY36224A (US07094801-20060822-C00173.png)
WO (2) WO2016011931A1 (US07094801-20060822-C00173.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955910C (en) * 2014-07-22 2022-07-12 Glaxosmithkline Intellectual Property Development Limited Tricyclic imidazo-pyrimidinone compounds as lp-pla2 inhibitors
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
EP3687980B1 (en) * 2017-09-26 2022-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Radiolabeled darapladib, analogs thereof and their use as imaging compounds
CN109988126B (zh) * 2017-12-29 2023-05-16 南京富润凯德生物医药有限公司 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用
CN109134523A (zh) * 2018-09-30 2019-01-04 中昊(大连)化工研究设计院有限公司 一种3，6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成新工艺
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
BR112022008786A2 (pt) * 2019-11-09 2022-07-26 Shanghai Simr Biotechnology Co Ltd Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
KR20230003136A (ko) * 2020-05-13 2023-01-05 뉴스코 바이오테크 리미티드 가교 환상 피리미디논류 화합물, 그의 제조방법, 그의 조성물 및 사용
CN113666930B (zh) * 2020-05-13 2022-10-25 上海纽思克生物科技有限公司 桥环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113861220B (zh) * 2020-06-30 2023-06-16 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN113912622B (zh) * 2020-07-10 2023-12-01 上海纽思克生物科技有限公司 三环嘧啶酮类化合物、其制备方法、其组合物和用途
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
CN114057740B (zh) * 2021-12-15 2024-04-02 上海赛默罗生物科技有限公司 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2024027116A1 (en) * 2022-08-04 2024-02-08 4B Technologies (Beijing) Co., Limited Dihydroimidazo-pyrimidinone compounds as lp-pla2 inhibitors and use thereof
CN118221687A (zh) * 2023-07-17 2024-06-21 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828326B2 (en) * 2002-08-13 2004-12-07 Warner-Lambert Company Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2012037782A1 (en) * 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
WO2013013503A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
WO2014114694A1 (en) * 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127143D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
ES2847883T3 (es) * 2010-12-17 2021-08-04 Glaxo Group Ltd Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
AU2012253615B2 (en) * 2011-05-09 2017-03-02 Eip Pharma, Llc Compositions and methods for treating Alzheimer's disease
US20130030012A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Compounds
CN103827118B (zh) * 2011-07-27 2016-03-09 葛兰素集团有限公司 双环嘧啶酮化合物
CN104024249A (zh) 2011-10-17 2014-09-03 埃南塔制药公司 丙型肝炎病毒抑制剂
JP6065786B2 (ja) 2012-09-14 2017-01-25 信越化学工業株式会社 化学増幅レジスト材料及びパターン形成方法
CA2899143A1 (en) * 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
CN103927116A (zh) * 2014-03-18 2014-07-16 兴唐通信科技有限公司 基于触屏设备的手势输入汉字的键盘和方法
CA2955910C (en) 2014-07-22 2022-07-12 Glaxosmithkline Intellectual Property Development Limited Tricyclic imidazo-pyrimidinone compounds as lp-pla2 inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828326B2 (en) * 2002-08-13 2004-12-07 Warner-Lambert Company Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2012037782A1 (en) * 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
WO2013013503A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
WO2014114694A1 (en) * 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors

Also Published As

Publication number Publication date
KR20170034889A (ko) 2017-03-29
TW201617348A (zh) 2016-05-16
RU2017105353A3 (US07094801-20060822-C00173.png) 2018-11-26
AU2015292049A1 (en) 2016-12-15
US11999746B2 (en) 2024-06-04
EP3172211B1 (en) 2019-07-03
US20170204108A1 (en) 2017-07-20
BR112016030939A2 (US07094801-20060822-C00173.png) 2017-08-22
CN106536521B (zh) 2018-08-03
CA2970537C (en) 2023-02-21
AU2015292049B2 (en) 2017-06-15
CA2955910C (en) 2022-07-12
EP3172208A4 (en) 2017-12-06
US10125141B2 (en) 2018-11-13
RU2017105353A (ru) 2018-08-22
AU2015292048A1 (en) 2016-12-15
JP6625604B2 (ja) 2019-12-25
EP3172208B1 (en) 2019-06-12
US20200055863A1 (en) 2020-02-20
CA2970537A1 (en) 2016-01-28
JP2017521456A (ja) 2017-08-03
JP2017520613A (ja) 2017-07-27
EP3172208A1 (en) 2017-05-31
BR112016030939B1 (pt) 2023-10-24
US20240300965A1 (en) 2024-09-12
US10428078B2 (en) 2019-10-01
CN106536525A (zh) 2017-03-22
UY36224A (es) 2016-01-29
RU2017105476A (ru) 2018-08-28
KR20170029516A (ko) 2017-03-15
US20190023715A1 (en) 2019-01-24
CA2955910A1 (en) 2016-01-28
CN106536525B (zh) 2019-05-03
EP3172211A4 (en) 2018-02-14
JP6625603B2 (ja) 2019-12-25
ES2744339T3 (es) 2020-02-24
CN106536521A (zh) 2017-03-22
ES2747636T3 (es) 2020-03-11
WO2016011930A1 (en) 2016-01-28
RU2690190C2 (ru) 2019-05-31
EP3172211A1 (en) 2017-05-31
US20170204109A1 (en) 2017-07-20
WO2016011931A1 (en) 2016-01-28
RU2017105476A3 (US07094801-20060822-C00173.png) 2019-02-28
US9783546B2 (en) 2017-10-10
AR101261A1 (es) 2016-12-07
BR112016028591A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
US11999746B2 (en) Compounds
JP6533217B2 (ja) Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
US8399480B2 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
KR101292348B1 (ko) 피리딘 유도체 및 그의 정신병적 장애의 치료에 있어서의용도
JP6276277B2 (ja) Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
CA2973760A1 (en) Pyrazine compounds for the treatment of infectious diseases
AU2012289492B2 (en) 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
CA3069554A1 (en) Inhibitors of leucine rich repeat kinase 2
CN114805389B (zh) 三环二氢咪唑并嘧啶酮衍生物、其制备方法、药物组合物和用途
CA2992820A1 (en) Dopamine d3 receptor antagonists having a bicyclo moiety
JP2020505398A (ja) 化合物
WO2024130095A9 (en) Compounds and compositions as cbp/p300 degraders and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired